Vancomycin Tolerance

Reports of clinical failures from increasing vancomycin MICs in S. aureus are growing in frequency. ^1,2 S. aureus isolates with vancomycin MICs greater than or equal to 1.5 µg/mL have resulted in twice the clinical failures versus the more normally observed population of less than or equal to 1 µg/mL. Clinical failures have been reported as high as 36 -percent.²

MicroPhage proposes to introduce the first product designed to rapidly assess patients for reduced vancomycin susceptibilities or "vancomycin MIC creep." Using our bacteriophage amplification platform, the MicroPhage Vancomycin Tolerance Test will work in parallel with the MicroPhage MRSA/MSSA Blood Culture Test to determine if a known S. aureus has an elevated vancomycin MIC of 1.5 µg/mL or greater.

By monitoring for these strains, clinicians can appropriately dose vancomycin or consider appropriate alternatives – days before traditional ID/AST results are available. This critical antibiotic information will ultimately help clinicians reduce suboptimal antibiotic treatments, complications, and costs, thereby improving patient outcomes.